clinical trial · NCT06840834
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Intergroupe Francophone de Cancerologie Thoracique·phase2·recruiting·n = 38
Pleural MesotheliomasIvonescimab
brief summary
Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy. 38 patients will be given second or third-line treatment with ivonescimab 20mg/kg every 3 weeks. An estimated 38 patients will be enrolled in approximately 20 centres. Patients will be treated for a maximum of 2 years, until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met. The null hypothesis is disease control rate (DCR) at 12 weeks ≤ 30%. The alternative hypothesis is DCR ≥ 55% at 12 weeks.
started
Jun 30, 2025
primary completion
Sep 30, 2026
completion
Mar 31, 2028
last updated
Aug 10, 2026
official title
Assessment of Ivonescimab as Salvage Treatment in Relapsing Pleural Mesothelioma Patients, Previously Treated by Immunotherapy and Standard Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol